

Deans, Directors, Department Chairs, and Administrative Officers

This memo is to alert you to the transition of responsibility from the Office of Contract and Grant Administration (OCGA) to the David Geffen School of Medicine Office of Clinical Trials (OCT) for the handling of incoming clinical trial subcontracts received from non-profit organizations in which the prime funding originates from a pharmaceutical company or similar industrial entity (e.g., Pfizer issues a contract to USC who issues a subcontract to UCLA).

As of June 1, 2008, all new projects which meet the UCOP/UCLA definition of “clinical trial” (see http://www.research.ucla.edu/ocga/memos/CT_Definition_Memo.pdf) that are subcontracted to UCLA from non-profit entities that are flowing through industry support (i.e., funds or in-kind test articles such as drug or device) will be handled by OCT. Regardless of whether the projects are sponsor-initiated or investigator-initiated, OCT will handle the subcontracts in a manner consistent with the industry supported trials that are directly contracted to UCLA, including application of the Clinical Trial F&A rate and all other relevant policies.

All pending subcontract awards in negotiation or set-up stage will continue to be handled by OCGA, as will all existing projects and future amendments to these projects. Any study with a mix of for-profit and non-profit support will be reviewed jointly by OCT and OCGA for assignment on a case-by-case basis depending on the circumstances.

If you have any questions related to this transition plan please feel free to contact Helene Orescan, Director of Contracting in the DGSOM Office of Clinical Trials at extension 4-0137 or via email at horescan@mednet.ucla.edu.

Sincerely,

Roberto Peccei

Vice Chancellor for Research